Screener
Spyre Therapeutics, Inc. SYRE Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
FAQ
- What is Spyre Therapeutics, Inc.'s shares (diluted)?
- Spyre Therapeutics, Inc. (SYRE) reported shares (diluted) of 78.5M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s shares (diluted) changed year-over-year?
- Spyre Therapeutics, Inc.'s shares (diluted) increased by 30.3% year-over-year, from 60.3M to 78.5M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s shares (diluted)?
- Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s shares (diluted) has grown at a 5.3% compound annual growth rate (CAGR), from 199.7M to 245.1M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Spyre Therapeutics, Inc.'s shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude